Niagen Bioscience, Inc. (NAGE) stock
NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3011% below fair value
$2.04+0.03 (+1.49%)
Close on Nov 17, 2026Market cap $161.42MP/E 17.0Yield –
Niagen Bioscience r&d expenses
Research and development expenses are spending on new products and technology.
Niagen Bioscience's R&D Expenses for the twelve months ending Sep 30, 2026 was $6.50M, up 9.5% year over year. For fiscal 2025 it was $6.33M, up 5.2% from the year before. Over ten years it grew 21.7% a year on average. The highest annual figure on record is $6.33M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.33M | +5.2% |
| FY2024 | Dec 31, 2024 | $6.02M | +21.3% |
| FY2023 | Dec 31, 2023 | $4.96M | +2.7% |
| FY2022 | Dec 31, 2022 | $4.83M | +25.9% |
| FY2021 | Dec 31, 2021 | $3.83M | +12.2% |
| FY2020 | Dec 31, 2020 | $3.42M | -22.7% |
| FY2019 | Dec 31, 2019 | $4.42M | -19.3% |
| FY2018 | Dec 31, 2018 | $5.48M | +36.7% |
| FY2017 | Dec 30, 2017 | $4.01M | +58.8% |
| FY2016 | Dec 31, 2016 | $2.52M | +182.9% |
| FY2015 | Jan 2, 2016 | $891.60K | +73.6% |
| FY2014 | Jan 3, 2015 | $513.67K | +283.2% |
| FY2013 | Dec 28, 2013 | $134.04K | -5.6% |
| FY2012 | Dec 29, 2012 | $142.00K | +46.7% |
| FY2011 | Dec 31, 2011 | $96.79K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.80M | +0.1% |
| Q2 FY2026 | Jun 30, 2026 | $1.51M | -3.4% |
| Q1 FY2026 | Mar 31, 2026 | $1.48M | +17.7% |
| Q4 FY2025 | Dec 31, 2025 | $1.71M | +30.0% |
| Q3 FY2025 | Sep 30, 2025 | $1.80M | +39.1% |
| Q2 FY2025 | Jun 30, 2025 | $1.57M | +19.1% |
| Q1 FY2025 | Mar 31, 2025 | $1.26M | -40.0% |
| Q4 FY2024 | Dec 31, 2024 | $1.32M | +13.5% |
| Q3 FY2024 | Sep 30, 2024 | $1.29M | +3.9% |
| Q2 FY2024 | Jun 30, 2024 | $1.32M | -3.6% |
| Q1 FY2024 | Mar 31, 2024 | $2.10M | +75.6% |
| Q4 FY2023 | Dec 31, 2023 | $1.16M | -9.4% |
| Q3 FY2023 | Sep 30, 2023 | $1.24M | +1.4% |
| Q2 FY2023 | Jun 30, 2023 | $1.37M | +9.6% |
| Q1 FY2023 | Mar 31, 2023 | $1.19M | +10.7% |
| Q4 FY2022 | Dec 31, 2022 | $1.28M | +22.4% |
| Q3 FY2022 | Sep 30, 2022 | $1.22M | +22.9% |
| Q2 FY2022 | Jun 30, 2022 | $1.25M | +24.0% |
| Q1 FY2022 | Mar 31, 2022 | $1.08M | +37.0% |
| Q4 FY2021 | Dec 31, 2021 | $1.05M | +20.1% |
| Q3 FY2021 | Sep 30, 2021 | $996.00K | +18.4% |
| Q2 FY2021 | Jun 30, 2021 | $1.00M | +12.2% |
| Q1 FY2021 | Mar 31, 2021 | $787.00K | -14.4% |
| Q4 FY2020 | Dec 31, 2020 | $870.00K | -23.6% |
| Q3 FY2020 | Sep 30, 2020 | $841.00K | -19.4% |
| Q2 FY2020 | Jun 30, 2020 | $895.00K | -16.3% |
| Q1 FY2020 | Mar 31, 2020 | $919.00K | -21.3% |
| Q4 FY2019 | Dec 31, 2019 | $1.14M | -10.7% |
| Q3 FY2019 | Sep 30, 2019 | $1.04M | -22.7% |
| Q2 FY2019 | Jun 30, 2019 | $1.07M | -24.4% |
| Q1 FY2019 | Mar 31, 2019 | $1.17M | -18.8% |
| Q4 FY2018 | Dec 31, 2018 | $1.28M | -12.3% |
| Q3 FY2018 | Sep 30, 2018 | $1.35M | +29.8% |
| Q2 FY2018 | Jun 30, 2018 | $1.41M | +164.7% |
| Q1 FY2018 | Mar 31, 2018 | $1.44M | +86.2% |
| Q4 FY2017 | Dec 30, 2017 | $1.45M | – |
| Q3 FY2017 | Sep 30, 2017 | $1.04M | – |
| Q4 FY2016 | Dec 31, 2016 | $534.17K | – |
| Q3 FY2016 | Oct 1, 2016 | $772.80K | – |
See a number that looks wrong?